Abstract
There are inconsistencies in the reporting of CD19 antigen status following treatment with CD19-targeted therapies. A majority of evidence comes from studies reporting small sample sizes. In this review, we systematically summarize published studies that have reported rates of CD19-negative relapse after treatment with either blinatumomab or CD19-directed CAR T-cell therapy and report the rates of CD19-negative relapse when evaluated in a standardized way across trials. CD19-negative relapse appears to occur more commonly in relapses following CAR T-cell therapy compared with blinatumomab, whether proportions are calculated among all treated patients (8.7% vs 4.5%) or among patients who relapse (30% vs 22.5%). The median (range) duration of follow-up was 29.3 (17.4-50.8) and 20.4 (6.9-49.0) months for publications on blinatumomab (n = 10) and CAR T-cell therapies (n = 23), respectively. There is a need for standardized reporting of CD19 antigen status in the setting of relapse following novel immunotherapies to inform clinical practice.
Original language | English (US) |
---|---|
Pages (from-to) | 1615-1633 |
Number of pages | 19 |
Journal | Leukemia and Lymphoma |
Volume | 64 |
Issue number | 10 |
DOIs | |
State | Published - 2023 |
Keywords
- Acute lymphoblastic leukemia
- blinatumomab
- CAR T-cell therapy
- CD19-negative relapse
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research